Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation

Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation

Background There is significant interest in NO pathway modulators, specifically type 5 phosphodiesterase inhibitors (PDE5is), to treat patients with a Fontan circulation. Trials, however, have had mixed results. The relationship between the NO pathway and clinical status in patients with Fontan circ...

Full description

Saved in:
Bibliographic Details
Main Authors: Ari Cedars, Cedric Manlhiot, Bhargava Kumar Chinni, Alexander R. Opotowsky, Kristian Becker, Anne Le, Pratik Khare, Jong Love Ko, Allen Everett, Shelby Kutty, Mark W. Russell, R. Mark Payne, Andrew M. Atz, Brian W. McCrindle, Rahul H. Rathod, Matthew Lewis, David Goldberg, Kevin Hill, Michelle Ploutz, Jon Detterich, Kurt Schumacher, Robert Whitehill, Daniel J. Penny, Mark Cartoski, Rachel Sullivan, Matthew Files, Ruchira Garg, Jonathan Wagner, Roni Jacobsen, Todd Nowlen, Scott Fletcher, Jennifer Conway, Gi Boem Kim, Fred Wu, Victor Zak
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Fontan
metabolomics
nitric oxide
type 5 phosophodiesterase inhibitor
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.038061
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.038061

Similar Items